These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 15605571)

  • 1. The path to corporate responsibility.
    Zadek S
    Harv Bus Rev; 2004 Dec; 82(12):125-32, 150. PubMed ID: 15605571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Who owns the long term? Perspectives from global business leaders.
    Lévy M; Eskew M; Bernotat WH; Barner M
    Harv Bus Rev; 2007; 85(7-8):54-60, 191. PubMed ID: 17642126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The virtue matrix. Calculating the return on corporate responsibility.
    Martin RL
    Harv Bus Rev; 2002 Mar; 80(3):68-75, 132. PubMed ID: 11894384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-performance marketing: an interview with Nike's Phil Knight. Interview by Geraldine E. Willigan.
    Knight P
    Harv Bus Rev; 1992; 70(4):90-101. PubMed ID: 10119721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Business Ethics 101 for the biotech industry.
    MacDonald C
    BioDrugs; 2004; 18(2):71-7. PubMed ID: 15046523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What's a business for?
    Handy C
    Harv Bus Rev; 2002 Dec; 80(12):49-55, 132. PubMed ID: 12510537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CEO as organizational architect: an interview with Xerox's Paul Allaire. Interview by Robert Howard.
    Allaire P
    Harv Bus Rev; 1992; 70(5):106-21. PubMed ID: 10121313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 2003 HBR list. Breakthrough ideas for tomorrow's business agenda.
    Harv Bus Rev; 2003 Apr; 81(4):92-8, 124. PubMed ID: 12687923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The competitive advantage of corporate philanthropy.
    Porter ME; Kramer MR
    Harv Bus Rev; 2002 Dec; 80(12):56-68, 133. PubMed ID: 12510538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No ordinary boot camp.
    Tichy NM
    Harv Bus Rev; 2001 Apr; 79(4):63-70, 166. PubMed ID: 11299694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Transparency in relations between multinational R&D pharmaceutical companies' corporate social responsibility activities and patient organizations in the Europe, Japan, and the United States].
    Kato M; Ishikawa H; Okuhara T; Kiuchi T
    Nihon Koshu Eisei Zasshi; 2019; 66(12):746-755. PubMed ID: 31875625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public health and corporate social responsibility: exploratory study on pharmaceutical companies in an emerging market.
    Dănescu T; Popa MA
    Global Health; 2020 Dec; 16(1):117. PubMed ID: 33302949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "The Big WHY": Philip Morris's failed search for corporate social value.
    McDaniel PA; Malone RE
    Am J Public Health; 2012 Oct; 102(10):1942-50. PubMed ID: 22897536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "What Is Our Story?" Philip Morris's Changing Corporate Narrative.
    McDaniel PA; Malone RE
    Am J Public Health; 2015 Oct; 105(10):e68-75. PubMed ID: 26270280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The historical development of business philanthropy: social responsibility in the new corporate economy.
    Marinetto M
    Bus Hist; 1999; 41(4):1-20. PubMed ID: 19455760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategy and society: the link between competitive advantage and corporate social responsibility.
    Porter ME; Kramer MR
    Harv Bus Rev; 2006 Dec; 84(12):78-92, 163. PubMed ID: 17183795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Building corporate character. Interview by Nan Stone.
    Hiatt A
    Harv Bus Rev; 1992; 70(2):94-104. PubMed ID: 10117372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covenant model of corporate compliance. "Corporate integrity" program meets mission, not just legal, requirements.
    Tuohey JF
    Health Prog; 1998; 79(4):70-5. PubMed ID: 10181597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avoiding integrity land mines.
    Heineman BW
    Harv Bus Rev; 2007 Apr; 85(4):100-8, 142. PubMed ID: 17432157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of China's Vaccine Incidents on the Operational Efficiency of Biopharmaceutical Companies.
    Chai KC; Tao R; Chang KC; Yang Y
    Front Public Health; 2020; 8():93. PubMed ID: 32322567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.